Biosimilar CT-P6 tested against herceptin in healthy volunteers
NCT ID NCT06687928
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 1 trial compared a single dose of CT-P6, a biosimilar of the cancer drug trastuzumab, to the approved Herceptin in 200 healthy men. The goal was to see if the two drugs behave similarly in the body and have comparable safety. Results will help determine if CT-P6 can be used as a more affordable alternative.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CT-P6 (a biosimilar of trastuzumab) and Herceptin (trastuzumab)
- What this could lead to
- If successful, this could show that CT-P6 works similarly to Herceptin, potentially offering a more affordable treatment option for certain cancers.
- What could go wrong
- This is an early-phase study in healthy men, not patients. It only checks how the drug moves through the body and safety, not whether it treats disease. Results may not predict real-world effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Celltrion
Yeonsu-gu, Incheon, 22006, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a new oral drug change future treatments? early safety trial begins
- Can brain scans unlock the secret to hearing in crowded rooms?
- Can a Light-Guided device make arterial sticks easier?
- Water workouts could be the key to back pain relief
- Could everyday disinfectants be harming us? a new study investigates
- Can a new drug keep the Heart's beat steady? trial puts verducatib to the test